Skip to contentB
Benitec Biopharma Inc.
B
BNTCBenitec Biopharma Inc. Q3 2024 · 10-Q
Revenue$0.00$0.00−100.0% vs Q3 2023 Net Income-$4.28M-$4.28MN/M vs Q3 2023 EPS Diluted-$0.23-$0.23N/M vs Q3 2023 Operating Income-$4,141,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Benitec Biopharma Inc. · CIK 1808898 · Engraved from SEC EDGAR
derived
ended Mar 31, 2024 · filed May 13, 2024 · 43 d after period end